Comparative Pharmacology
Head-to-head clinical analysis: ADASUVE versus LYPQOZET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADASUVE versus LYPQOZET.
ADASUVE vs LYPQOZET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Loxapine (the active ingredient in ADASUVE) is a dibenzoxazepine antipsychotic agent that acts primarily as a dopamine D2 receptor antagonist. It also exhibits affinity for serotonin 5-HT2A, 5-HT2C, and histamine H1 receptors, and to a lesser extent, alpha-adrenergic and muscarinic receptors. The exact mechanism of its antipsychotic effect is thought to involve dopamine and serotonin receptor blockade.
LYPQOZET is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the central nervous system by inhibiting the reuptake of serotonin at the presynaptic serotonin transporter, leading to increased synaptic levels of serotonin.
Inhalation: 10 mg as a single dose via oral inhalation up to a maximum of 2 doses within a 24-hour period, each dose separated by at least 2 hours. For agitation associated with schizophrenia or bipolar I disorder.
Oral, 75 mg once daily.
None Documented
None Documented
Mean terminal half-life of loxapine is 6-8 hours; active metabolite 7-hydroxyloxapine (amoxapine) has half-life of ~30 hours. Clinically, steady state achieved within 3-5 days.
Terminal elimination half-life is 22-28 hours in adults, allowing once-daily dosing. Extended half-life supports sustained therapeutic levels.
Primarily renal (30-40% as unchanged drug and metabolites; ~50% as loxapine metabolites), with minor biliary/fecal elimination (<10%).
Primarily renal (75% unchanged) and fecal/biliary (20% as metabolites); <5% unchanged in feces.
Category C
Category C
Antipsychotic
Antipsychotic